Amgen Inc at Guggenheim Partners Healthcare Talks Oncology Days Transcript
All right. Hello. I'm Michael Schmidt, senior biotech analyst with Guggenheim Securities, and it's my great pleasure to welcome Amgen to this year's Virtual Guggenheim Oncology Day.
With us today, we have Gregory Friberg, who is the Vice President of Global Development at Amgen; as well as Arvind Sood, who most of you know, who's heading up Investor Relations at Amgen. Welcome, guys, and thanks so much for joining us this year.
Thanks, Michael.
Thank you, Michael.
Questions & Answers
I thought, in the interest of time, I will jump right into Q&A. Maybe a bigger picture question upfront. Oncology is obviously one of the biggest and fastest-growing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
